Premium
Myelodysplastic Syndrome Following Treatment of Malignant Melanoma with Vincristine, ACNU, and Dacarbazine
Author(s) -
Kageshita Toshiro,
Kuribayashi Noriomi,
Ono Tomomichi
Publication year - 2000
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2000.tb02147.x
Subject(s) - medicine , vincristine , dacarbazine , bone marrow , melanoma , peripheral blood , chemotherapy , myelodysplastic syndromes , pathology , oncology , cancer research , cyclophosphamide
Therapy‐related myelodysplastic syndrome is a rare adverse effect in melanoma patients elicited by chemotherapy. We report a case of myelodysplastic syndrome following treatment of malignant melanoma with alkylating agents. Peripheral blood showed a remarkable suppression of three cell lineages, and the bone marrow was slightly hypercellular. However, no morphological abnormalities were detected in the peripheral blood or the bone marrow, and chromosomal analysis was normal.